期刊文献+

胰岛素与西格列汀联合用药方案对老年2型糖尿病的治疗效果分析 被引量:4

下载PDF
导出
摘要 目的:探讨胰岛素与西格列汀联合用药方案对老年2型糖尿病的治疗效果。方法:2018年1-12月收治老年2型糖尿病患者74例,分为两组各37例,对照组采用胰岛素单一用药方案,试验组采用胰岛素与西格列汀联合用药方案,比较两组预后情况。结果:试验组治疗1周后空腹血糖、餐后2 h血糖以及糖化血红蛋白均明显优于对照组,差异有统计学意义(P<0.05)。试验组治疗3个月后显效率、有效率均明显高于对照组,差异有统计学意义(P<0.05)。试验组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:2型糖尿病患者采用胰岛素与西格列汀联合用药方案的治疗效果明显优于单纯胰岛素给药方案。
作者 陆勇 沈玉婧
出处 《中国社区医师》 2019年第13期60-60,62,共2页 Chinese Community Doctors
  • 相关文献

参考文献6

二级参考文献57

  • 1HortonES, SilbermanC, DavisKL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database[J].Diabetes Care, 2010, 33(8):1759-1765. DOI: 10.2337/dc09-2062.
  • 2BaruahMP, ChaudhuryT, SethiBK, et al. Liraglutide in type 2 diabetes mellitus[J].J Indian Med Assoc, 2012, 110(5):335-338.
  • 3de WitHM, VervoortGM, JansenHJ, et al. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreasesinsulin dose in patients with type 2 diabetes:a 26 week, randomised clinical trial (ELEGANT)[J]. Diabetologia, 2014, 57(9):1812-1819. DOI: 10.1007/s00125-014-3302-0.
  • 4CerielloA, SportielloL, RafanielloC, et al. DPP-4 inhibitors: pharmacological differences and their clinical implications[J]. Expert Opin Drug Saf, 2014, 13(9):57-68. DOI: 10.1517/14740338.2014.944862.
  • 5KimMH, LeeMK. The incretins and pancreatic beta-cells: use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus[J]. Korean Diabetes J, 2010, 34(1):2-9. DOI: 10.4093/kdj.2010.34.1.2.
  • 6LiCJ, LiJ, ZhangQM, et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J].Cardiovasc Diabetol, 2012, 15(11):134-142. DOI: 10.1186/1475-2840-11-142.
  • 7KuhadiyaND, MalikR, BelliniNJ, et al.Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus[J]. Endocr Pract, 2013, 19(6):963-967. DOI: 10.4158/EP13065.OR.
  • 8Standl E, Schne11 O. Alpha-glucosidase inhibitors 2012- cardiovascular considerations and trial evaluation [ J ]. Diab Vasc Dis Res, 2012, 9 (3): 163-169.
  • 9Gautier JF, Choukem SP, Girard J. Physiology of incretins ( GIP and GLP-1 ) and abnormalities in type 2 diabetes [ J ]. Diabetes Metab, 2008, 34 Suppl 2: S65-S72.
  • 10Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose : a continuous glucose monitoring-based pilot study [ J ]. Diabetes Technol Ther, 2013, 15(5) :378-385.

共引文献158

同被引文献42

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部